Value of FDG-PET/CT Examinations in Different Cancers of Children, Focusing on Lymphomas

[1]  L. Dalla-Pozza,et al.  18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  C. Portwine,et al.  PET imaging for pediatric oncology: An assessment of the evidence , 2010, Pediatric blood & cancer.

[3]  Chang-Guhn Kim,et al.  The Efficacy of Dual Time Point F-18 FDG PET Imaging for Grading of Brain Tumors , 2010, Clinical nuclear medicine.

[4]  K. Frey,et al.  FDG PET imaging of childhood sarcomas , 2009, Pediatric blood & cancer.

[5]  E. Guedj,et al.  Utility of FDG‐PET/CT in the follow‐up of neuroblastoma which became MIBG‐negative , 2008, Pediatric blood & cancer.

[6]  R. Hawkins,et al.  Diagnostic value of PET/CT for the staging and restaging of pediatric tumors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  H. Jadvar,et al.  PET and PET/CT in pediatric oncology. , 2007, Seminars in nuclear medicine.

[8]  Z. Keidar,et al.  The incremental value of 18F-FDG PET/CT in paediatric malignancies , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  I. Roca,et al.  PET/CT in paediatrics: it is time to increase its use! , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  S Fanti,et al.  18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  K. Juergens,et al.  Is PET/CT necessary in paediatric oncology? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Ur Metser,et al.  Role of 18F-FDG PET/CT in Staging and Follow-up of Lymphoma in Pediatric and Young Adult Patients , 2006, Journal of computer assisted tomography.

[13]  W. Martin,et al.  Utility of FDG-PET/CT in Follow-Up of Children Treated for Hodgkin and Non-Hodgkin Lymphoma , 2006, Journal of pediatric hematology/oncology.

[14]  K. Juergens,et al.  PET/CT with diagnostic CT in the evaluation of childhood sarcoma. , 2006, AJR. American journal of roentgenology.

[15]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Y. Erdi,et al.  Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 23: 4643-4651 , 2005 .

[17]  S. Spunt,et al.  PET/CT in the evaluation of childhood sarcomas. , 2005, AJR. American journal of roentgenology.

[18]  M. A. Smith,et al.  The impact of PET scanning on management of paediatric oncology patients , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  J. Eary,et al.  Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography , 2002, Cancer.

[20]  R A Koeppe,et al.  Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. , 1995, Radiology.

[21]  M. Hirsh,et al.  I-131 metaiodobenzylguanidine: Diagnostic use in neuroblastoma patients in relapse: S. Heyman, A. Evans, and G.J. D'Angio. Med Pediatr Oncol 16:337–340, (November–December), 1988 , 1989 .

[22]  A. Evans,et al.  I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse. , 1988, Medical and pediatric oncology.